Innovent Biologics Stock Probability of Future Pink Sheet Price Finishing Under 0.87
| IVBXF Stock | USD 4.85 0.24 4.72% |
Innovent |
Innovent Biologics Alerts and Suggestions
In today's market, stock alerts give investors the competitive edge they need to time the market and increase returns. Checking the ongoing alerts of Innovent Biologics for significant developments is a great way to find new opportunities for your next move. Suggestions and notifications for Innovent Biologics can help investors quickly react to important events or material changes in technical or fundamental conditions and significant headlines that can affect investment decisions.| Innovent Biologics generated a negative expected return over the last 90 days | |
| Innovent Biologics has high historical volatility and very poor performance | |
| Innovent Biologics has high likelihood to experience some financial distress in the next 2 years | |
| The company reported the revenue of 4.27 B. Net Loss for the year was (3.14 B) with profit before overhead, payroll, taxes, and interest of 2.98 B. | |
| Innovent Biologics has accumulated about 8.32 B in cash with (2.02 B) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 5.67, which can makes it an attractive takeover target, given it will continue generating positive cash flow. |
Innovent Biologics Price Density Drivers
Market volatility will typically increase when nervous long traders begin to feel the short-sellers pressure to drive the market lower. The future price of Innovent Pink Sheet often depends not only on the future outlook of the current and potential Innovent Biologics' investors but also on the ongoing dynamics between investors with different trading styles. Because the market risk indicators may have small false signals, it is better to identify suitable times to hedge a portfolio using different long/short signals. Innovent Biologics' indicators that are reflective of the short sentiment are summarized in the table below.
| Common Stock Shares Outstanding | 1.5 B |
Innovent Biologics Technical Analysis
Innovent Biologics' future price can be derived by breaking down and analyzing its technical indicators over time. Innovent Pink Sheet technical analysis helps investors analyze different prices and returns patterns as well as diagnose historical swings to determine the real value of Innovent Biologics. In general, you should focus on analyzing Innovent Pink Sheet price patterns and their correlations with different microeconomic environments and drivers.
Innovent Biologics Predictive Forecast Models
Innovent Biologics' time-series forecasting models is one of many Innovent Biologics' pink sheet analysis techniques aimed to predict future share value based on previously observed values. Time-series forecasting models are widely used for non-stationary data. Non-stationary data are called the data whose statistical properties, e.g., the mean and standard deviation, are not constant over time, but instead, these metrics vary over time. This non-stationary Innovent Biologics' historical data is usually called time series. Some empirical experimentation suggests that the statistical forecasting models outperform the models based exclusively on fundamental analysis to predict the direction of the pink sheet market movement and maximize returns from investment trading.
Things to note about Innovent Biologics
Checking the ongoing alerts about Innovent Biologics for important developments is a great way to find new opportunities for your next move. Our stock alerts and notifications screener for Innovent Biologics help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.
| Innovent Biologics generated a negative expected return over the last 90 days | |
| Innovent Biologics has high historical volatility and very poor performance | |
| Innovent Biologics has high likelihood to experience some financial distress in the next 2 years | |
| The company reported the revenue of 4.27 B. Net Loss for the year was (3.14 B) with profit before overhead, payroll, taxes, and interest of 2.98 B. | |
| Innovent Biologics has accumulated about 8.32 B in cash with (2.02 B) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 5.67, which can makes it an attractive takeover target, given it will continue generating positive cash flow. |
Other Information on Investing in Innovent Pink Sheet
Innovent Biologics financial ratios help investors to determine whether Innovent Pink Sheet is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in Innovent with respect to the benefits of owning Innovent Biologics security.